Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo - Zhang, H; Xu, X; Gajewiak, J (Cancer Res, 2009)
et al.